Treeline Biosciences has signed a clinical trial collaboration and supply agreement with Roche for a Phase I study assessing the combination of Treeline’s BCL6 degrader, TLN-121, with Roche’s CD20×CD3 T-cell-engaging bispecific antibodies, glofitamab (Columvi) and mosunetuzumab (Lunsumio), in patients with B-cell lymphomas (BCL).
The trial will assess the combinations in separate cohorts, including individuals with diffuse large B-cell lymphoma (DLBCL).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Under the collaboration, Treeline Biosciences will sponsor and oversee the Phase I dose-escalation and expansion study, with Roche supplying glofitamab and mosunetuzumab for particular expansion cohorts.
Treeline intends to start combination dosing in these cohorts in the fourth quarter of 2026.
Treeline co-founder and CEO Josh Bilenker said: “CD20×CD3 T-cell-engaging bispecific antibodies such as glofitamab and mosunetuzumab have already transformed the treatment of B-cell lymphomas. We are excited to build on that progress in collaboration with Roche.
“We have generated exciting preclinical data suggesting that TLN-121 enhances the anti-tumour activity of both CD20×CD3 T-cell-engaging bispecific antibodies and CD19 CAR-T cell therapy. These results were predicted by published studies that showed BCL6 impairs the formation of an effective immune synapse between T-cells and B-cells.”
TLN-121 has shown single-agent activity, including complete responses, in an ongoing Phase I trial in late-line DLBCL, follicular lymphoma and T follicular helper peripheral T-cell lymphoma.
Treeline is a clinical-stage biopharmaceutical company with a pipeline in oncology, neurology and immunology.
Last month, Evexta Bio and Roche entered a clinical trial collaboration and supply agreement for a Phase Ib study investigating the combination of rupitasertib and giredestrant in patients with advanced or metastatic breast cancer.
This marks the first clinical collaboration for Evexta Bio involving its investigational compound rupitasertib and for Roche with giredestrant, its selective estrogen receptor degrader (SERD).
